达雷妥尤单抗-来那度胺-地塞米松与标准治疗方案在不适合移植初治骨髓瘤中的疗效比较
PEGASUS研究采用锚定间接治疗比较,将MAIA试验中达雷妥尤单抗-来那度胺-地塞米松(D-Rd)组的无进展生存期(PFS)与Flatiron健康电子病历数据库中接受硼替佐米-来那度胺-地塞米松(VRd)或硼替佐米-地塞米松(Vd)治疗的患者进行比较。经倾向评分加权后,D-Rd相比Rd(HR 0.54;95%CI 0.42,0.71)、VRd(HR 0.68;95%CI 0.48,0.98)和Vd(HR 0.48;95%CI 0.33,0.69)均与显著更低的进展或死亡风险相关。
要点
- D-Rd较Rd显著降低进展或死亡风险(HR 0.54;95%CI 0.42,0.71)。
- 间接比较显示D-Rd较VRd显著降低进展或死亡风险(HR 0.68;95%CI 0.48,0.98)。
- 间接比较显示D-Rd较Vd显著降低进展或死亡风险(HR 0.48;95%CI 0.33,0.69)。
核心结论
- 在缺乏D-Rd与VRd或Vd头对头试验的情况下,本间接治疗比较可能有助于为不适合移植的初治多发性骨髓瘤患者的治疗选择提供信息。
研究设计与样本
- PEGASUS研究为锚定间接治疗比较,使用MAIA试验中D-Rd与Rd比较的个体患者数据,以及Flatiron健康电子病历去标识数据库中主要来自美国社区肿瘤实践的患者数据。
- 以来那度胺-地塞米松(Rd)为共同锚点,利用MAIA内D-Rd vs Rd及Flatiron Health内VRd vs Rd、Vd vs Rd的直接比较HR进行间接比较。
- 应用MAIA纳入/排除标准及倾向评分加权后,Flatiron Health患者在所测基线特征上与MAIA试验人群相似。
主要发现
- 基于MAIA内直接比较,D-Rd治疗与Rd相比进展或死亡风险显著更低(HR 0.54;95%CI 0.42,0.71)。
- 基于间接治疗比较,D-Rd与VRd相比进展或死亡风险显著更低(HR 0.68;95%CI 0.48,0.98)。
- 基于间接治疗比较,D-Rd与Vd相比进展或死亡风险显著更低(HR 0.48;95%CI 0.33,0.69)。
临床怎么用
- 原文结论指出,在缺乏头对头试验的情况下,本间接治疗比较可能有助于为不适合移植的初治多发性骨髓瘤患者的治疗选择提供信息。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Daratumumab in combination with lenalidomide-dexamethasone (D-Rd) recently received FDA approval for the treatment of transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). The present PEGASUS study compared progression-free survival (PFS) in patients treated with D-Rd in the MAIA trial and patients treated with common standard-of-care regimens from the Flatiron Health electronic health record-derived deidentified database, which has data from patients treated primarily at community-based oncology practices in the United States. Individual-level patient data from both data sources were used to perform an anchored indirect treatment comparison (ITC) of D-Rd to bortezomib-lenalidomide-dexamethasone (VRd) and bortezomib-dexamethasone (Vd); lenalidomide-dexamethasone (Rd) was the common anchor for the ITC. Hazard ratios (HRs) reflecting direct comparisons of PFS within MAIA (D-Rd vs Rd) and Flatiron Health (VRd vs Rd; Vd vs Rd) were used to make ITCs for D-Rd vs VRd and Vd, respectively. After application of MAIA inclusion/exclusion criteria and propensity-score weighting, the Flatiron Health patients resembled the MAIA trial population on measured baseline characteristics. Based on the direct comparison within MAIA, treatment with D-Rd was associated with a significantly lower risk of progression or death compared to Rd (HR 0.54; 95% CI 0.42, 0.71). Based on the ITCs, D-Rd was associated with a significantly lower risk of progression or death compared to VRd (HR 0.68; 95% CI 0.48, 0.98) and Vd (HR 0.48; 95% CI 0.33, 0.69). In the absence of head-to-head trials comparing D-Rd to VRd or Vd, the present ITC may help inform treatment selection in transplant-ineligible patients with NDMM.
引用
- Durie BGM, Kumar SK, Usmani SZ, et al. Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: Efficacy in transplant-ineligible untreated myeloma. Am J Hematol. 2020. PMID: 32804408. doi:10.1002/ajh.25963
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。